- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA requests label and packaging changes for certain topical antiseptic products
- Lupin gets FDA approval for generic Mycobutin
- Reports: ESI may start 'price war' over new hepatitis C drugs
- Senate passes Drug Quality and Security Act
ALLEGAN, Mich. — The Food and Drug Administration has approved a generic treatment made by Perrigo for fungal infections of the vagina, the company said.
Perrigo announced the approval of butoconazole nitrate 2% vaginal cream, a generic version of KV Pharmaceutical's Gynazole-1, used to treat vulvovaginal candidiasis, an infection caused by Candida fungus. KV voluntarily discontinued selling the drug in January 2009 due to manufacturing problems.
The drug maker said it was the first company to file a complete regulatory application for the drug with the FDA, thus entitling it to 180 days of market exclusivity. Perrigo will launch the drug at the end of the year under a collaboration with KV.
Gynazole had annual sales of $28 million before its voluntary discontinuation, according to Wolters Kluwer Health.